Last 12 months
Inside the activity.
1 purchase rows · 32 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 8 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 14 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 05, 2023 Filed Apr 6, 2023 00:57 UTC |
Hessekiel JeffreyEVP, General Counsel & Sec
|
Exercise / conversionOption (right to buy) · Derivative | 13,930 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000939767-23-000041 · wf-form4_168074265582525.xml · derivative · entry 5 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,710 Underlying: Common Stock · 13,930 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 97,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 22, 2020. Read SEC document |
| April 05, 2023 Filed Apr 6, 2023 00:57 UTC |
Hessekiel JeffreyEVP, General Counsel & Sec
|
SaleCommon Stock | 38,930 | $20.01 | $778,989.30 |
DisclosureSEC source: 0000939767-23-000041 · wf-form4_168074265582525.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 582,435 F4 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2022. F5 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.06. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 5 to this Form 4. Read SEC document |
| April 05, 2023 Filed Apr 6, 2023 00:57 UTC |
Hessekiel JeffreyEVP, General Counsel & Sec
|
Exercise / conversionCommon Stock | 13,930 | $14.74 | $205,328.20 |
DisclosureSEC source: 0000939767-23-000041 · wf-form4_168074265582525.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 621,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 00:57 UTC |
Hessekiel JeffreyEVP, General Counsel & Sec
|
GrantCommon Stock | 79,719 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000041 · wf-form4_168074265582525.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 607,435 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2024 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 204,921 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 00:28 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GrantCommon Stock | 313,185 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000040 · wf-form4_168074090649421.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 642,318 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2024 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 630,601 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 00:27 UTC |
Aftab DanaCSO/EVP Disc & Trans Research
|
GrantCommon Stock | 68,331 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000039 · wf-form4_168074082916477.xml · nonDerivative · entry 1 Aftab Dana · CIK 0001959132 · CSO/EVP Disc & Trans Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 419,803 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2024 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 278,421 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 00:25 UTC |
Senner Christopher J.EVP and CFO
|
GrantCommon Stock | 85,414 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000038 · wf-form4_168074073189294.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 590,077 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2024 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 225,796 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 00:24 UTC |
Goodman Vicki LEVP, Prod Dev & Med Aff &CMO
|
GrantCommon Stock | 82,566 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000037 · wf-form4_168074064086550.xml · nonDerivative · entry 1 Goodman Vicki L · CIK 0001901477 · EVP, Prod Dev & Med Aff &CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,654 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2024 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 246,383 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 00:22 UTC |
Haley Patrick J.EVP, Commercial
|
GrantCommon Stock | 79,719 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000036 · wf-form4_168074056722050.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,577 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2024 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 227,087 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:22 UTC |
WYSZOMIERSKI JACK LDirector
|
Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000939767-23-000031 · wf-form4_167883973386085.xml · derivative · entry 3 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 26, 2016. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:22 UTC |
WYSZOMIERSKI JACK LDirector
|
SaleCommon Stock | 15,300 | $16.61 | $254,133.00 |
DisclosureSEC source: 0000939767-23-000031 · wf-form4_167883973386085.xml · nonDerivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,467 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 8, 2023. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.52 to $16.70. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:22 UTC |
WYSZOMIERSKI JACK LDirector
|
Exercise / conversionCommon Stock | 40,000 | $6.30 | $252,000.00 |
DisclosureSEC source: 0000939767-23-000031 · wf-form4_167883973386085.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 19,575 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:59 UTC |
Hessekiel JeffreyEVP, General Counsel & Sec
|
Exercise / conversionOption (right to buy) · Derivative | 27,860 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000939767-23-000030 · wf-form4_167789158170498.xml · derivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,640 Underlying: Common Stock · 27,860 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 97,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 22, 2020. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:59 UTC |
Hessekiel JeffreyEVP, General Counsel & Sec
|
SaleCommon Stock | 77,860 | $17.13 | $1,333,741.80 |
DisclosureSEC source: 0000939767-23-000030 · wf-form4_167789158170498.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,716 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2022. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.28. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:59 UTC |
Hessekiel JeffreyEVP, General Counsel & Sec
|
Exercise / conversionCommon Stock | 27,860 | $14.74 | $410,656.40 |
DisclosureSEC source: 0000939767-23-000030 · wf-form4_167789158170498.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 125,202 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 00:56 UTC |
Aftab DanaCSO/EVP Disc & Trans Research
|
Exercise / conversionOption (right to buy) · Derivative | 82,490 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000939767-23-000029 · wf-form4_167771857999028.xml · derivative · entry 7 Aftab Dana · CIK 0001959132 · CSO/EVP Disc & Trans Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,490 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 00:56 UTC |
Aftab DanaCSO/EVP Disc & Trans Research
|
SaleCommon Stock | 82,490 | $17.50 | $1,443,575.00 |
DisclosureSEC source: 0000939767-23-000029 · wf-form4_167771857999028.xml · nonDerivative · entry 4 Aftab Dana · CIK 0001959132 · CSO/EVP Disc & Trans Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,472 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.50 to $17.51. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 00:56 UTC |
Aftab DanaCSO/EVP Disc & Trans Research
|
Exercise / conversionCommon Stock | 82,490 | $14.74 | $1,215,902.60 |
DisclosureSEC source: 0000939767-23-000029 · wf-form4_167771857999028.xml · nonDerivative · entry 3 Aftab Dana · CIK 0001959132 · CSO/EVP Disc & Trans Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2023 Filed Mar 2, 2023 00:56 UTC |
Aftab DanaCSO/EVP Disc & Trans Research
|
Exercise / conversionOption (right to buy) · Derivative | 10 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000939767-23-000029 · wf-form4_167771857999028.xml · derivative · entry 6 Aftab Dana · CIK 0001959132 · CSO/EVP Disc & Trans Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,490 Underlying: Common Stock · 10 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2023 Filed Mar 2, 2023 00:56 UTC |
Aftab DanaCSO/EVP Disc & Trans Research
|
SaleCommon Stock | 10 | $17.50 | $175.00 |
DisclosureSEC source: 0000939767-23-000029 · wf-form4_167771857999028.xml · nonDerivative · entry 2 Aftab Dana · CIK 0001959132 · CSO/EVP Disc & Trans Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,472 Read SEC document |
| February 27, 2023 Filed Mar 2, 2023 00:56 UTC |
Aftab DanaCSO/EVP Disc & Trans Research
|
Exercise / conversionCommon Stock | 10 | $14.74 | $147.40 |
DisclosureSEC source: 0000939767-23-000029 · wf-form4_167771857999028.xml · nonDerivative · entry 1 Aftab Dana · CIK 0001959132 · CSO/EVP Disc & Trans Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 210,090 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 02:08 UTC |
Garber Alan MDirector
|
Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000939767-23-000028 · wf-form4_167720447178170.xml · derivative · entry 3 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 26, 2016. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 02:08 UTC |
Garber Alan MDirector
|
SaleCommon Stock | 40,000 | $17.49 | $699,600.00 |
DisclosureSEC source: 0000939767-23-000028 · wf-form4_167720447178170.xml · nonDerivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,417 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 2, 2022. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.39 to $17.55. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 02:08 UTC |
Garber Alan MDirector
|
Exercise / conversionCommon Stock | 40,000 | $6.30 | $252,000.00 |
DisclosureSEC source: 0000939767-23-000028 · wf-form4_167720447178170.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:46 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Tax withholdingCommon Stock | 11,522 | $18.08 | $208,317.76 |
DisclosureSEC source: 0000939767-23-000027 · wf-form4_167668835038706.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,133 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on December 15, 2021. F2 · balance_after: Includes 317,416 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:44 UTC |
Haley Patrick J.EVP, Commercial
|
Tax withholdingCommon Stock | 1,556 | $18.08 | $28,132.48 |
DisclosureSEC source: 0000939767-23-000026 · wf-form4_167668825419022.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,858 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on December 15, 2021. F2 · balance_after: Includes 147,368 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:42 UTC |
Senner Christopher J.EVP and CFO
|
Tax withholdingCommon Stock | 5,278 | $18.08 | $95,426.24 |
DisclosureSEC source: 0000939767-23-000025 · wf-form4_167668814014763.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,663 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on December 15, 2021. F2 · balance_after: Includes 140,382 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:41 UTC |
Hessekiel JeffreyEVP, General Counsel & Sec
|
Tax withholdingCommon Stock | 1,929 | $18.08 | $34,876.32 |
DisclosureSEC source: 0000939767-23-000024 · wf-form4_167668805342567.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577,716 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on December 15, 2021. F2 · balance_after: Includes 125,202 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:38 UTC |
Goodman Vicki LEVP, Prod Dev & Med Aff &CMO
|
Tax withholdingCommon Stock | 17,299 | $18.08 | $312,765.92 |
DisclosureSEC source: 0000939767-23-000022 · wf-form4_167668786613786.xml · nonDerivative · entry 1 Goodman Vicki L · CIK 0001901477 · EVP, Prod Dev & Med Aff &CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,088 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded January 4, 2022. F2 · balance_after: Includes 163,817 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:39 UTC |
Aftab DanaCSO/EVP Disc & Trans Research
|
Tax withholdingCommon Stock | 1,529 | $18.08 | $27,644.32 |
DisclosureSEC source: 0000939767-23-000023 · wf-form4_167668795382584.xml · nonDerivative · entry 1 Aftab Dana · CIK 0001959132 · CSO/EVP Disc & Trans Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,472 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on December 15, 2021. F2 · balance_after: Includes 210,090 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 09, 2023 Filed Feb 11, 2023 00:56 UTC |
FELDBAUM CARL BDirector
|
Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000939767-23-000021 · wf-form4_167607695196458.xml · derivative · entry 3 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 26, 2016. Read SEC document |
| February 09, 2023 Filed Feb 11, 2023 00:56 UTC |
FELDBAUM CARL BDirector
|
SaleCommon Stock | 40,000 | $17.78 | $711,200.00 |
DisclosureSEC source: 0000939767-23-000021 · wf-form4_167607695196458.xml · nonDerivative · entry 2 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,701 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.76 to $17.82. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 09, 2023 Filed Feb 11, 2023 00:56 UTC |
FELDBAUM CARL BDirector
|
Exercise / conversionCommon Stock | 40,000 | $6.30 | $252,000.00 |
DisclosureSEC source: 0000939767-23-000021 · wf-form4_167607695196458.xml · nonDerivative · entry 1 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 10,180 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 06, 2023 Filed Feb 9, 2023 01:17 UTC |
Haley Patrick J.EVP, Commercial
|
Exercise / conversionOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000939767-23-000020 · wf-form4_167590540517971.xml · derivative · entry 5 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2023-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 25,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020. Read SEC document |
| February 06, 2023 Filed Feb 9, 2023 01:17 UTC |
Haley Patrick J.EVP, Commercial
|
SaleCommon Stock | 25,000 | $17.37 | $434,250.00 |
DisclosureSEC source: 0000939767-23-000020 · wf-form4_167590540517971.xml · nonDerivative · entry 2 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,414 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 1, 2022. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.30 to $17.50. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| February 06, 2023 Filed Feb 9, 2023 01:17 UTC |
Haley Patrick J.EVP, Commercial
|
Exercise / conversionCommon Stock | 25,000 | $4.20 | $105,000.00 |
DisclosureSEC source: 0000939767-23-000020 · wf-form4_167590540517971.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · EVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 151,866 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 30, 2023 Filed Feb 2, 2023 01:33 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GiftCommon Stock | 37,994 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000006 · wf-form4_167530160621659.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,340,320 F1 · kind: On January 30, 2023, the Reporting Person gifted 37,994 shares of Exelixis, Inc. common stock ("Common Stock") to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended. F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. Read SEC document |
| January 30, 2023 Filed Feb 2, 2023 01:33 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GiftCommon Stock | 37,994 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000006 · wf-form4_167530160621659.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,655 F1 · kind: On January 30, 2023, the Reporting Person gifted 37,994 shares of Exelixis, Inc. common stock ("Common Stock") to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended. F2 · balance_after: Includes 340,655 shares of Common Stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 24, 2023 Filed Jan 27, 2023 01:59 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000939767-23-000005 · wf-form4_167478476355424.xml · derivative · entry 6 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2023-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 150,000 shares of Common Stock, became fully exercisable on February 11, 2020. Read SEC document |
| January 24, 2023 Filed Jan 27, 2023 01:59 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Tax withholdingCommon Stock | 62,006 | $17.36 | $1,076,424.16 |
DisclosureSEC source: 0000939767-23-000005 · wf-form4_167478476355424.xml · nonDerivative · entry 4 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,649 F4 · shares: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 37,994 shares of Common Stock on the net exercise of a stock option to purchase 100,000 shares of Common Stock. The Issuer withheld 62,006 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on January 24, 2023 of $17.36. Read SEC document |
| January 24, 2023 Filed Jan 27, 2023 01:59 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 100,000 | $4.20 | $420,000.00 |
DisclosureSEC source: 0000939767-23-000005 · wf-form4_167478476355424.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2023 Filed Jan 10, 2023 00:58 UTC |
Aftab DanaCSO/EVP Disc & Trans Research
|
GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000004 · wf-form4_167331232427458.xml · nonDerivative · entry 1 Aftab Dana · CIK 0001959132 · CSO/EVP Disc & Trans Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,001 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Subject to the terms of the restricted stock unit award, the restricted stock units will vest as follows: 25,000 on February 15, 2024 and, thereafter, 25,000 on each of February 15, 2025, 2026 and 2027. F3 · balance_after: Includes 213,838 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:09 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000939767-22-000122 · wf-form4_167123936903484.xml · derivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:09 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
SaleCommon Stock | 20,000 | $15.88 | $317,600.00 |
DisclosureSEC source: 0000939767-22-000122 · wf-form4_167123936903484.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,958 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.71 to $16.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:09 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionCommon Stock | 20,000 | $4.20 | $84,000.00 |
DisclosureSEC source: 0000939767-22-000122 · wf-form4_167123936903484.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 120,383 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 07, 2022 Filed Jan 27, 2023 01:59 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GiftCommon Stock | 106,010 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000005 · wf-form4_167478476355424.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,302,326 F1 · kind: On December 7, 2022, the Reporting Person gifted 106,010 shares of Exelixis, Inc. common stock ("Common Stock") to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended. F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. Read SEC document |
| December 07, 2022 Filed Jan 27, 2023 01:59 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GiftCommon Stock | 106,010 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000005 · wf-form4_167478476355424.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,655 F1 · kind: On December 7, 2022, the Reporting Person gifted 106,010 shares of Exelixis, Inc. common stock ("Common Stock") to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended. F2 · balance_after: Includes 340,655 shares of Common Stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 29, 2022 Filed Dec 2, 2022 01:11 UTC |
POSTE GEORGEDirector
|
Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000939767-22-000116 · wf-form4_166994345555782.xml · derivative · entry 3 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 26, 2016. Read SEC document |
| November 29, 2022 Filed Dec 2, 2022 01:11 UTC |
POSTE GEORGEDirector
|
SaleCommon Stock | 40,000 | $16.68 | $667,200.00 |
DisclosureSEC source: 0000939767-22-000116 · wf-form4_166994345555782.xml · nonDerivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,189 Read SEC document |
| November 29, 2022 Filed Dec 2, 2022 01:11 UTC |
POSTE GEORGEDirector
|
Exercise / conversionCommon Stock | 40,000 | $6.30 | $252,000.00 |
DisclosureSEC source: 0000939767-22-000116 · wf-form4_166994345555782.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 19,575 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.